249 related articles for article (PubMed ID: 31936235)
1. Envelope-Specific IgG3 and IgG1 Responses Are Associated with Clearance of Acute Hepatitis C Virus Infection.
Walker MR; Eltahla AA; Mina MM; Li H; Lloyd AR; Bull RA
Viruses; 2020 Jan; 12(1):. PubMed ID: 31936235
[TBL] [Abstract][Full Text] [Related]
2. B cell immunodominance in primary hepatitis C virus infection.
Brasher NA; Eltahla AA; Underwood A; Boo I; Rizzetto S; Walker MR; Rodrigo C; Luciani F; Maher L; Drummer HE; Tedla N; Lloyd AR; Bull RA
J Hepatol; 2020 Apr; 72(4):670-679. PubMed ID: 31785346
[TBL] [Abstract][Full Text] [Related]
3. Broad Anti-Hepatitis C Virus (HCV) Antibody Responses Are Associated with Improved Clinical Disease Parameters in Chronic HCV Infection.
Swann RE; Cowton VM; Robinson MW; Cole SJ; Barclay ST; Mills PR; Thomson EC; McLauchlan J; Patel AH
J Virol; 2016 May; 90(9):4530-4543. PubMed ID: 26912610
[TBL] [Abstract][Full Text] [Related]
4. Clearance of hepatitis C virus is associated with early and potent but narrowly-directed, Envelope-specific antibodies.
Walker MR; Leung P; Eltahla AA; Underwood A; Abayasingam A; Brasher NA; Li H; Wu BR; Maher L; Luciani F; Lloyd AR; Bull RA
Sci Rep; 2019 Sep; 9(1):13300. PubMed ID: 31527718
[TBL] [Abstract][Full Text] [Related]
5. Limited humoral immunity in hepatitis C virus infection.
Chen M; Sällberg M; Sönnerborg A; Weiland O; Mattsson L; Jin L; Birkett A; Peterson D; Milich DR
Gastroenterology; 1999 Jan; 116(1):135-43. PubMed ID: 9869611
[TBL] [Abstract][Full Text] [Related]
6. Antigenic regions within the hepatitis C virus envelope 1 and non-structural proteins: identification of an IgG3-restricted recognition site with the envelope 1 protein.
Sällberg M; Rudén U; Wahren B; Magnius LO
Clin Exp Immunol; 1993 Mar; 91(3):489-94. PubMed ID: 7680297
[TBL] [Abstract][Full Text] [Related]
7. Establishment of human clones producing neutralizing human monoclonal antibodies to the envelope E1/E2 protein of hepatitis C virus by EBV immortalization of immune CD22⁺ B cells.
Tabll A; El Abd Y; El Din NG; El Shenawy R; Abdelhafez TH; El Awady M; El-Mohamady H; Viazov S
Hum Antibodies; 2013; 22(3-4):55-65. PubMed ID: 24961863
[TBL] [Abstract][Full Text] [Related]
8. Studies on the role of neutralizing antibodies against envelope genes in resolving HCV pseudo-particles infection.
Rafique S; Idrees M; Ali A; Iqbal M
Mol Biol Rep; 2014 Jun; 41(6):3945-50. PubMed ID: 24566682
[TBL] [Abstract][Full Text] [Related]
9. The hepatitis C virus glycan shield and evasion of the humoral immune response.
Helle F; Duverlie G; Dubuisson J
Viruses; 2011 Oct; 3(10):1909-32. PubMed ID: 22069522
[TBL] [Abstract][Full Text] [Related]
10. Broadly Neutralizing Antibodies Targeting New Sites of Vulnerability in Hepatitis C Virus E1E2.
Colbert MD; Flyak AI; Ogega CO; Kinchen VJ; Massaccesi G; Hernandez M; Davidson E; Doranz BJ; Cox AL; Crowe JE; Bailey JR
J Virol; 2019 Jul; 93(14):. PubMed ID: 31068427
[TBL] [Abstract][Full Text] [Related]
11. Immunoglobulin allotypes influence IgG antibody responses to hepatitis C virus envelope proteins E1 and E2.
Pandey JP; Luo Y; Elston RC; Wu Y; Philp FH; Astemborski J; Thomas DL; Netski DM
Hum Immunol; 2008 Mar; 69(3):158-64. PubMed ID: 18396207
[TBL] [Abstract][Full Text] [Related]
12. Anti-envelope antibody responses in individuals at high risk of hepatitis C virus who resist infection.
Swann RE; Mandalou P; Robinson MW; Ow MM; Foung SK; McLauchlan J; Patel AH; Cramp ME
J Viral Hepat; 2016 Nov; 23(11):873-880. PubMed ID: 27405885
[TBL] [Abstract][Full Text] [Related]
13. HCV Broadly Neutralizing Antibodies Use a CDRH3 Disulfide Motif to Recognize an E2 Glycoprotein Site that Can Be Targeted for Vaccine Design.
Flyak AI; Ruiz S; Colbert MD; Luong T; Crowe JE; Bailey JR; Bjorkman PJ
Cell Host Microbe; 2018 Nov; 24(5):703-716.e3. PubMed ID: 30439340
[TBL] [Abstract][Full Text] [Related]
14. A weak neutralizing antibody response to hepatitis C virus envelope glycoprotein enhances virus infection.
Meyer K; Banerjee A; Frey SE; Belshe RB; Ray R
PLoS One; 2011; 6(8):e23699. PubMed ID: 21887300
[TBL] [Abstract][Full Text] [Related]
15. Broadly Neutralizing Antibody Mediated Clearance of Human Hepatitis C Virus Infection.
Kinchen VJ; Zahid MN; Flyak AI; Soliman MG; Learn GH; Wang S; Davidson E; Doranz BJ; Ray SC; Cox AL; Crowe JE; Bjorkman PJ; Shaw GM; Bailey JR
Cell Host Microbe; 2018 Nov; 24(5):717-730.e5. PubMed ID: 30439341
[TBL] [Abstract][Full Text] [Related]
16. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.
Law JLM; Logan M; Wong J; Kundu J; Hockman D; Landi A; Chen C; Crawford K; Wininger M; Johnson J; Mesa Prince C; Dudek E; Mehta N; Tyrrell DL; Houghton M
J Virol; 2018 Jun; 92(11):. PubMed ID: 29540595
[TBL] [Abstract][Full Text] [Related]
17. Clinical evaluation of titration of hepatitis C virus core antibody and its subclasses.
Taura Y; Fujiyama S; Kawano S; Sato S; Tanaka M; Goto M; Chikazawa H; Shibata J; Mizuno K; Sato T
J Gastroenterol Hepatol; 1995; 10(3):270-6. PubMed ID: 7548802
[TBL] [Abstract][Full Text] [Related]
18. A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells.
Rosa D; Campagnoli S; Moretto C; Guenzi E; Cousens L; Chin M; Dong C; Weiner AJ; Lau JY; Choo QL; Chien D; Pileri P; Houghton M; Abrignani S
Proc Natl Acad Sci U S A; 1996 Mar; 93(5):1759-63. PubMed ID: 8700831
[TBL] [Abstract][Full Text] [Related]
19. Assessment of humoral immune response in patients with chronic hepatitis C virus infection.
El-Kady IM
Egypt J Immunol; 2004; 11(2):141-7. PubMed ID: 16734126
[TBL] [Abstract][Full Text] [Related]
20. Acceleration of hepatitis C virus envelope evolution in humans is consistent with progressive humoral immune selection during the transition from acute to chronic infection.
Liu L; Fisher BE; Dowd KA; Astemborski J; Cox AL; Ray SC
J Virol; 2010 May; 84(10):5067-77. PubMed ID: 20200239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
